Dominique Bertrand
A5037619345- Renal Transplantation Outcomes and Treatments
- Renal Diseases and Glomerulopathies
- Pneumocystis jirovecii pneumonia detection and treatment
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Organ Transplantation Techniques and Outcomes
- Complement system in diseases
- Neurological Complications and Syndromes
- Long-Term Effects of COVID-19
- Transplantation: Methods and Outcomes
- Organ Donation and Transplantation
- Renal and Vascular Pathologies
- Vasculitis and related conditions
- Pharmacological Effects and Toxicity Studies
- Blood groups and transfusion
- Cytomegalovirus and herpesvirus research
- French Urban and Social Studies
- Pregnancy and Medication Impact
- Healthcare Systems and Practices
- Polyomavirus and related diseases
- Liver Disease and Transplantation
- HIV/AIDS drug development and treatment
- Airway Management and Intubation Techniques
- Dialysis and Renal Disease Management
- Health, Medicine and Society
Université de Rouen Normandie
2016-2025
Centre Hospitalier Universitaire de Rouen
2015-2024
Agence de la Biomédecine
2020
Délégation Paris 7
2019
University of Health Science
2019
University of Birmingham
2019
Medical University of Warsaw
2019
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
2017
Hôpital Charles-Nicolle
2015-2016
Université Paris Cité
2012-2014
Notwithstanding the ongoing coronavirus disease-2019 (Covid-19) pandemic, information on its clinical presentation and prognosis in recipients of a kidney transplant remain scanty. The aim this registry-based observational study was to explore characteristics outcomes transplants included French nationwide Registry Solid Organ Transplant Recipients with Covid-19. Covid-19 diagnosed symptomatic patients who had positive PCR assay for SARS-CoV-2 or having typical lung lesions imaging. Clinical...
There are no studies which have compared the risk of severe COVID-19 and related mortality between transplant recipients nontransplant patients. We enrolled two groups patients hospitalized for COVID-19, that is, kidney (KTR) from French Registry Solid Organ Transplant (n = 306) a single-center cohort 795). An analysis was performed among subgroups matched age factors or mortality. Severe defined as admission (or transfer) to an intensive care unit, need mechanical ventilation, death. were...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a high rate of mortality in patients ESKD, and vaccination hoped to prevent infection.
Atypical hemolytic uremic syndrome (HUS) is associated with high recurrence rates after kidney transplant, devastating outcomes. In late 2011, experts in France recommended the use of highly individualized complement blockade-based prophylaxis eculizumab to prevent post-transplant atypical HUS throughout country.To evaluate this strategy's effect on transplant prognosis, we conducted a retrospective multicenter study from large French nationwide registry, enrolling all adult patients who had...
In C3 glomerulopathy (C3G), the alternative pathway of complement is frequently overactivated by autoantibodies that stabilize convertase C3bBb. Anti-C3b and anti-factor B (anti-FB) IgG have been reported in three patients with C3G. We screened a cohort 141 C3G Ig-associated membranoproliferative GN (Ig-MPGN) for anti-FB anti-C3b using ELISA. identified seven IgG, five IgG. Of these 15 patients, ten were diagnosed Ig-MPGN. Among those available data, 92% had nephrotic syndrome, 64% AKI, 67%...
The aim of this study (ClinicalTrials.gov, NCT01744470) was to determine the efficacy and safety two different doses extended-release tacrolimus (TacER) in kidney transplant recipients (KTRs) between 4 12 mo after transplantation. Stable steroid-free KTRs were randomized (1:1) mo: Group A had a 50% reduction TacER dose with targeted trough level (C0) >3 μg/L; group B no change (TacER C0 7–12 μg/L). primary outcome estimated GFR at 1 year. Of 300 patients, intent-to-treat analysis included...
Significance Statement Antibody-mediated rejection (AMR) in renal allografts, which is usually caused by antibodies (Abs) directed against HLAs, associated with a poor transplant outcome. However, evidence of AMR the absence anti-HLA Abs suggests presence non-anti–HLA Abs, presumed to react other antigens on endothelial cells. The authors describe clinicopathologic profiles kidney recipients who experienced acute microvascular inflammation within 3 months after transplantation donor-specific...
Vitamin D sufficiency is associated with a reduced risk of fractures, diabetes mellitus, cardiovascular events, and cancers, which are frequent complications after renal transplantation. The VITALE (VITamin supplementation in renAL transplant recipients) study multicenter double-blind randomized trial, including nondiabetic adult recipients serum 25-hydroxy vitamin (25(OH) D) levels <30 ng/mL, 12 to 48 months transplantation receive high (100 000 IU) or low doses (12 cholecalciferol every 2...
Abstract Background Belatacept (bela) rescue therapy seems to be a valuable option for calcineurin inhibitor chronic toxicity in kidney transplantation. Nevertheless, the risk of infection associated with bela is not well reported. Methods We report rate opportunistic infections (OPI) after switch multicentric cohort 280 transplant patients. Results Forty-two OPI occurred 34 patients (12.1%), on average 10.8 ± 11.3 months switch. With cumulative exposure 5128 treatment, we found an incidence...
Although kidney transplantation carries a survival benefit compared with dialysis, mortality, especially the first year after transplantation, is high in recipients older than 70. The aim of this study was to evaluate early death and graft failure, determine risk factors associated these events specific population.
Transplant recipients receiving a kidney from an extended-criteria donor (ECD) are exposed to calcineurin inhibitor (CNI) nephrotoxicity, as demonstrated by severe delayed graft function and/or low GFR. Belatacept is nonnephrotoxic drug that indicated alternative CNIs. We reported 25 cases of conversion CNI belatacept due intolerance within the first 6 mo after transplantation. The mean age was 59 years, and 24 patients received ECD kidneys. At date medication switch, 12 displayed calculated...
Solid phase immunoassays improved the detection and determination of antigen-specificity donor-specific antibodies (DSA) to human leukocyte antigens (HLA). The widespread use SPI in kidney transplantation also introduced new clinical dilemmas, such as whether patients should be monitored for DSA pre- or post-transplantation. Pretransplant screening through has become standard practice are readily determined case suspected rejection. However, monitoring recipients with stable graft function...
Compared to other analytical methods, matrix‐assisted laser desorption ionization mass spectrometry (MALDI‐MS) presents several unique advantages for the structural characterization of degradation products carbohydrates. Our final goal is implement this technique as a high‐throughput platform, with aim exploring natural bio‐diversity discover new carbohydrate depolymerizing enzymes. In approach, variety carbohydrates will be used enzymes substrates and MALDI‐MS employed monitor...
Immunosuppressed organ-transplanted patients are considered at risk for severe forms of COVID-19. Moreover, exaggerated innate and adaptive immune responses might be involved in progression the disease. However, no data on response to SARS-CoV-2 transplanted currently available. Here, we report first assessment antibody T cell 11 kidney-transplanted recovered from RT-PCR-confirmed (n = 5) or initially suspected 6) After reduction immunosuppressive therapy, COVID-19 transplant were able mount...